Piper Jaffray Cos. set a $22.00 price objective on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) in a research note issued to investors on Monday morning. The firm currently has a a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on ITCI. Leerink Swann reiterated a buy rating on shares of Intra-Cellular Therapies in a research note on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a hold rating to a buy rating and set a $42.00 price target for the company in a research note on Wednesday, June 29th. Cowen and Company reiterated a buy rating on shares of Intra-Cellular Therapies in a research note on Wednesday, June 29th. SunTrust Banks Inc. lowered shares of Intra-Cellular Therapies from a buy rating to a neutral rating and reduced their price target for the stock from $60.00 to $15.00 in a research note on Thursday, September 29th. Finally, Royal Bank Of Canada reduced their price target on shares of Intra-Cellular Therapies from $74.00 to $49.00 and set an outperform rating for the company in a research note on Thursday, September 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Intra-Cellular Therapies has an average rating of Hold and an average price target of $42.00.

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) traded down 5.30% during mid-day trading on Monday, reaching $14.29. 600,826 shares of the company’s stock traded hands. Intra-Cellular Therapies has a 12-month low of $14.25 and a 12-month high of $59.96. The stock has a 50 day moving average of $35.84 and a 200 day moving average of $36.87. The company’s market cap is $618.06 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.08. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.02 million. The firm’s revenue for the quarter was up 283.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.61) earnings per share. On average, equities research analysts predict that Intra-Cellular Therapies will post ($3.19) earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of ITCI. Royal Bank of Canada increased its position in shares of Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares in the last quarter. Legal & General Group Plc increased its position in shares of Intra-Cellular Therapies by 22.2% in the first quarter. Legal & General Group Plc now owns 4,085 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 742 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of Intra-Cellular Therapies during the second quarter valued at $155,000. Mycio Wealth Partners LLC increased its position in shares of Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 550 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 546 shares in the last quarter. 70.15% of the stock is currently owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.